布斯皮龙调节皮质-状的马振荡,以改善运动障碍
Han Liu1,2,3, Ruizuo Wang1,2,3, Yuming Xu1,2,3
1The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Journal of Parkinson's disease
|October 7, 2025
概括
布斯皮龙通过抑制病理性马振荡和皮层-状网络过活性,有效地减少帕金森病 (PD) 中的Levodopa诱导的运动障碍 (LID). 这为LID症状提供了潜在的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 在帕金森病 (PD) 中,Levodopa诱导的运动障碍 (LID) 与过度的马振荡有关.
- 布斯皮龙是一种5-HT1A受体激动剂,主要用于焦虑症,但正在研究其在PD中的潜力.
- 病理性振荡活动和皮层-层功能连接性与LID病理生理学有关.
研究的目的:
- 在LID的小鼠模型中研究buspirone在减轻动力障碍方面的有效性.
- 评估buspirone对皮层-状回路内的病态振荡活动的影响.
- 为了评估buspirone对LID中的皮层-层功能连接的影响.
主要方法:
- 电生理学和运动行为数据从假,6-氧多巴胺 (6-OHDA) 损伤的PD模型和LID大鼠中收集.
- 用巴斯皮龙治疗LID大鼠,以检查行为和电生理学变化.
- 分析的重点是β和gamma振荡,非周期性活动和皮质-状功能连接.
主要成果:
- LID老鼠表现出过度的马振荡 (50-150 Hz) 和增强的马频段皮层-状功能连接.
- 布斯皮龙的使用显著降低了动力障碍的严重程度,并抑制了病理性马活性和连接性.
- 布斯皮龙治疗降低了无周期组件 (50-150 Hz),而不会干扰莱沃多巴的抗帕金森症作用.
结论:
- 过度的马振荡是LID的关键电生理学标志物.
- 改变的马波段皮质 - 状网络连接有助于LID病理生理学.
- 布斯皮龙作为治疗帕金森病LID的新型治疗剂显示出前景.
相关概念视频
01:24Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
2.3K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.3K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
761
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
761
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.0K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.6K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.6K